From
Dr. Paula Escobar
Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Feb 2025 · 1 min read
In brief
In brief
This real-world study evaluates outcomes of the KEYNOTE-522 neoadjuvant immunotherapy regimen (pembrolizumab plus chemotherapy) in early-stage triple-negative breast cancer patients. The research examines whether pathologic complete response rates observed in clinical trials translate to routine clinical practice settings.
Written by the GCMD Library team from the article.
Annals of Surgical Oncology - This study aimed to determine if the neoadjuvant (NAT) KEYNOTE-522 regimen was associated with higher rates of pathologic complete response (pCR), corresponding to...
Educational content from recorded physician discussions — not medical advice. Talk to your (or your child's) care team about your situation.
Article
Breast Conserving Therapy Versus Mastectomy: Outcomes Across Different Clinical Characteristics
Paula Escobar · Published Dec 2026
Podcast
Endoscopic nipple-sparing mastectomy: minimally invasive breast cancer surgery
Paula Escobar · 14 min · Published Jul 2026
Article
Impact of Second Opinions on Time to Treatment of Breast Cancer
Paula Escobar · Published Jul 2026
Article
Case Study: Endoscopic Nipple-Sparing Bilateral Mastectomy Improves Outcomes
Paula Escobar · Published Apr 2026
Video
Breast Surgical Oncologist Paula Escobar, MD (Spanish)
Paula Escobar · 2 min · Published Dec 2024
Video
Breast Surgical Oncologist Paula Escobar, MD
Paula Escobar · 1 min · Published Dec 2024
Only a few other public items share this author — go deeper there →